Entero Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENTO research report →
About the company
Entero Therapeutics, Inc. , a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.
- CEO
- Jason David Sawyer
- IPO
- 2016
- Employees
- 2
- HQ
- Boca Raton, FL, US
Price Chart
- Market Cap
- $13.58M
- P/E
- -0.94
- P/S
- 198.66
- P/B
- 0.87
- EV/EBITDA
- -2.04
- Div Yield
- 0.00%
- Gross Margin
- -775.58%
- Op Margin
- -13264.41%
- Net Margin
- -11664.78%
- ROE
- -18.69%
- ROIC
- -26.65%
- Revenue
- $36.25K · 0.00%
- Net Income
- $-6,553,578 · 63.71%
- EPS
- $-4.16 · -7.22%
- Op Income
- $-7,083,438
- FCF YoY
- 38.13%
- 52W High
- $5.84
- 52W Low
- $0.97
- 50D MA
- $4.07
- 200D MA
- $2.24
- Beta
- 1.19
- Avg Volume
- 216.27K
Get TickerSpark's AI analysis on ENTO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ENTO coverage
Recent articles, reports, and earnings notes.
No research on ENTO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENTO report →Similar companies
Peers in the same neighborhood.